09926.HK
Akeso, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 101.20
+11.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.9B | 3.0B | 2.1B | 4.5B | 837.7M |
| Cost of Revenue | 1.3B | 635.4M | 289.0M | 133.2M | 103.1M |
| Gross Profit | 4.6B | 2.3B | 1.8B | 4.4B | 734.5M |
| Operating Expenses | |||||
| R&D Expense | 2.9B | 1.5B | 1.2B | 1.3B | 1.3B |
| SG&A Expense | 3.3B | 1.7B | 1.2B | 1.1B | 751.7M |
| General & Admin Expense | 407.6M | — | 203.6M | 200.1M | 199.0M |
| Selling & Marketing Expense | 1.9B | — | 1.0B | 890.4M | 552.7M |
| Other Expenses | (127.2M) | 3.00 | (54.3M) | — | — |
| Total Operating Expenses | 6.1B | 3.2B | 2.3B | 2.3B | 2.1B |
| Cost and Expenses | 7.4B | 3.9B | 2.7B | 2.5B | 2.2B |
| Operating Income (EBIT) | (1.5B) | (918.2M) | (570.4M) | 2.0B | (1.3B) |
| Non-Operating | |||||
| Interest Income | 472.5M | 291.5M | 206.4M | 119.7M | 22.0M |
| Interest Expense | 128.9M | 127.6M | 68.3M | 87.0M | 43.3M |
| Net Interest Income | 343.6M | 163.9M | 138.1M | 32.7M | (21.3M) |
| Other Non-Op Income/Expense | (361.2M) | (231.0M) | 69.3M | (101.7M) | (82.0M) |
| Non-Operating Income (excl Interest) | 137.3M | — | 172.1M | 14.7M | 197.3M |
| EBT (Pre-Tax Income) | (1.8B) | (1.1B) | (501.1M) | 1.9B | (1.4B) |
| Income Tax Expense | 3.7M | — | — | 174.0K | — |
| Bottom Line | |||||
| Net Income | (1.8B) | (1.1B) | (514.5M) | 2.0B | (1.2B) |
| Earnings from Cont. Ops | (1.8B) | (1.1B) | (501.1M) | 1.9B | (1.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.8B) | (1.1B) | (514.5M) | 2.0B | (1.2B) |
| Per Share | |||||
| Basic EPS | (HK$2.00) | (HK$1.20) | (HK$0.60) | HK$2.42 | (HK$1.42) |
| Diluted EPS | (HK$2.00) | (HK$1.20) | (HK$0.60) | HK$2.42 | (HK$1.42) |
| Revenue Per Share | HK$6.43 | HK$3.30 | HK$2.50 | HK$5.40 | HK$1.02 |
| Shares | |||||
| Basic Shares Outstanding | 918.6M | 902.9M | 851.0M | 837.8M | 825.0M |
| Diluted Shares Outstanding | 918.6M | 902.9M | 851.0M | 837.8M | 825.0M |
| Profitability Metrics | |||||
| EBITDA | (1.5B) | (663.1M) | (605.0M) | 2.2B | (1.3B) |
| D&A | 391.0M | 255.1M | 125.3M | 142.8M | 105.8M |
| EBIT | (1.9B) | (918.2M) | (730.3M) | 2.0B | (1.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026